News Search Results
Dec 11, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL)." Although the press release described the data in positive terms, the press release reported that adverse events occurred in two patients,
More news about: Pomerantz LLP
Dec 11, 2025, 08:00 ET HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025
242MOTitle: HCB101, a Differentiated SIRPα Fusion Protein, Demonstrates Favorable Safety and Early Antitumor Activity Across Solid Tumors and LymphomaFirst Author: Dr. Fangling Ning, Affiliated Hospital of Binzhou Medical UniversityDate / Time: 11 December 2025
More news about: HanchorBio Inc.
Dec 10, 2025, 08:00 ET Bantam Pharmaceutical Announces First Patient Treated in BTM-3566 Phase 1 Clinical Trial at Princess Margaret Cancer Centre in Toronto
limited treatment options."Bantam's Phase 1 program is active in both the U.S. and Canada to study BTM-3566 in lymphomas and solid tumors. The lymphoma cohort includes patients with relapsed/refractory mature B-cell lymphomas. The solid tumor cohort includes a broad range of cancers such as head and
More news about: Bantam Pharmaceutical, LLC
Dec 10, 2025, 08:00 ET Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S.
More news about: Kazia Therapeutics Limited
Dec 09, 2025, 08:30 ET Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Proceeds strengthen cash position and support commercial launch of LYMPHIR™, a novel cancer immunotherapy for cutaneous T-cell lymphoma (CTCL)CRANFORD, N.J., Dec. 9, 2025 /PRNewswire/ -- Citius Oncology,
More news about: Citius Oncology, Inc.
Dec 09, 2025, 08:00 ET Curis Provides Updated Data from its Frontline AML Triplet Study
inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL), in the TakeAim Leukemia Phase 1/2 study (CA-4948-102)
More news about: Curis, Inc.
Dec 09, 2025, 07:30 ET Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
unacceptable toxicity.About Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaChronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are forms of slow-growing non-Hodgkin lymphoma that develop from white blood cells known as lymphocytes.4 CLL is one
More news about: Eli Lilly and Company
Dec 09, 2025, 07:30 ET Pirtobrutinib Outperforms Bendamustine Plus Rituximab for Previously Untreated CLL/SLL
when compared with bendamustine plus rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The data were presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.
More news about: American Society of Hematology
Dec 09, 2025, 05:00 ET Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025
Hematology (ASH) Annual Meeting. Highlights include golidocitinib, a Janus kinase 1 (JAK1) only inhibitor, in T-cell lymphoma, and birelentinib, a non-covalent LYN/BTK dual inhibitor, in B-cell lymphoma.
More news about: Dizal Pharmaceutical
Dec 08, 2025, 07:30 ET Recordati Rare Diseases Showcases Real-World Evidence Studies That Advance Understanding of Castleman Disease (CD) at the American Society of Hematology (ASH) Annual Meeting
is a rare cytokine-driven disorder that may be life-threatening and can affect people of any age. Its symptoms often resemble those of malignant lymphoma, autoimmune, or infectious diseases, making it difficult to diagnose. iMCD is a subtype of Castleman disease (CD), which is a group of rare conditions
More news about: Recordati
Dec 08, 2025, 07:00 ET HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma at ASH 2025
monotherapy data demonstrate cytopenia-sparing safety, broad pharmacologic window, and early clinical activity in relapsed/refractory non-Hodgkin lymphoma (NHL)TAIPEI, SHANGHAI, and SAN FRANCISCO, Dec. 8, 2025 /PRNewswire/
More news about: HanchorBio Inc.
Dec 08, 2025, 07:00 ET Karyopharm to Participate in Baird's Biotech Discovery Series
targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit
More news about: Karyopharm Therapeutics Inc.
Dec 07, 2025, 16:30 ET Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
unacceptable toxicity.About Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaChronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are forms of slow-growing non-Hodgkin lymphoma that develop from white blood cells known as lymphocytes.4 CLL is one
More news about: Eli Lilly and Company
Dec 07, 2025, 07:30 ET Studies Point to a Growing Role for New Therapies and Immunotherapies in Treating Blood Cancers
[this regimen] is curative, but it's certainly the beginning of a bright era for chemo-free therapy for follicular lymphoma."Follicular lymphoma is a slow-growing non-Hodgkin lymphoma that can progress to a more aggressive form. Patients who see their cancer return after an initial round of treatment
More news about: American Society of Hematology
Dec 07, 2025, 03:58 ET 【直擊2025 ASH】突破BTKi耐藥和複雜核型的困境！亞盛醫藥口頭報告利生妥®中國關鍵註冊研究數據
registrational phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)利沙托克拉單藥治療布魯頓酪氨酸激酶抑制劑（BTKi）治療失敗的復發/
More news about: 亞盛醫藥
Dec 07, 2025, 01:18 ET All Approved Indications of Five Akeso's Innovative Drugs Included in China's Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs
first-line treatment of squamous NSCLC, first-line treatment of NPC, ≥3L treatment of NPC, and ≥3L treatment of relapsed/refractory classical Hodgkin lymphoma (R/R cHL).Ebdarokimab (IL-12/IL-23): Psoriasis Indication Now Covered by NRDLEbdarokimab is China's first independently developed
More news about: Akeso, Inc.
Dec 06, 2025, 22:40 ET Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
world.[vii]In the updated NRDL, Jaypirca® is newly listed for the treatment of adult patients with relapsed or refractory mantle cell lymphoma after at least two types of systemic therapy, including a BTK inhibitor. Its NRDL inclusion will benefit heavily-treated MCL patients that previously
More news about: Innovent Biologics
Dec 06, 2025, 09:45 ET Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting
in patients with relapsed or refractory CD19-positive B-cell malignancies. As of the November 30, 2025 data cutoff, two patients with non-Hodgkin's lymphoma had completed multiple GT801 administrations without lymphodepleting chemotherapy, demonstrating the feasibility of generating functional CAR-T cells
More news about: Vivacta Biotechnology Co., Ltd.
Dec 06, 2025, 09:30 ET Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
infectious disease specialists.In cases of refractory IEC-EC, consider additional workup to exclude alternative etiologies, including T-cell lymphoma of the GI tract, which has been reported in the post marketing setting.Secondary Malignancies: Patients treated with CARVYKTI®
More news about: Johnson & Johnson
Dec 04, 2025, 08:37 ET Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
in the U.S. in December 2025.About Cutaneous T-cell LymphomaCutaneous T-cell lymphoma is a type of cutaneous non-Hodgkin lymphoma (NHL) that comes in a variety of forms and is the most common type of cutaneous lymphoma. In CTCL, T-cells, a type of lymphocyte that plays a role in the
More news about: Citius Oncology, Inc.
Dec 04, 2025, 06:00 ET AvenCell Therapeutics Announces IND Clearance and EMA Approval of Clinical Trial Application (CTA) for the QUADvance Study, a Phase I/II trial evaluating AVC-203, a Novel Allogeneic CD19/CD20 CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory B-cell malignancies
early success and promising activity and safety of our ongoing clinical program of allogeneic CAR-T in AML (NCT05949125) by now advancing into B Cell Lymphoma with what we believe to be the most scientifically compelling allogeneic technology in the industry," said Andrew Schiermeier, AvenCell's President
More news about: AvenCell Therapeutics, Inc.
Dec 04, 2025, 03:00 ET iOnctura initiates Phase I/II trial in patients with myelofibrosis ahead of new non-clinical data at ASH
disease."In addition to the two posters related to MF, trials in progress posters for the ongoing investigations of roginolisib in peripheral T-cell lymphoma and chronic lymphocytic leukemia (CLL) will also be presented at ASH.iOnctura poster presentations at the 67th ASH Annual Meeting
More news about: iOnctura
Dec 03, 2025, 12:59 ET U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
unacceptable toxicity.About Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaChronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are forms of slow-growing non-Hodgkin lymphoma that develop from white blood cells known as lymphocytes.5 CLL is one
More news about: Eli Lilly and Company
Dec 03, 2025, 12:00 ET ImpriMed to Present Ex Vivo Drug Sensitivity Data in Acute Myeloid Leukemia in Oral Presentation at American Society of Hematology Annual Meeting
predictive biomarkers that de-risk clinical development. Supporting indications include acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. ImpriMed operates two laboratories: the Silicon Valley lab is A2LA-accredited to ISO 17025, and the Seoul lab is KGMP-certified
More news about: ImpriMed
Dec 03, 2025, 10:20 ET OneOncology and OneR Partner Practice Investigators to Present Broad Portfolio of Data at the 2025 American Society of Hematology Annual Meeting
Key Highlights25 scientific abstracts spanning lymphoma, leukemia, and multiple myeloma underscore the essential role of community-based investigators in accelerating blood cancer research.• Data show bi-specific antibodies can be safely administered
More news about: OneOncology, LLC.